CANGRELOR
| Brand name | KENGREAL |
|---|---|
| Active ingredient | CANGRELOR |
| Strength | 50MG/VIAL |
| Dosage form | POWDER |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | June 2015 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 9439921 | July 2035 | product |
| 9295687 | July 2035 | product |
| 9700575 | July 2035 | product |
| 10039780 | July 2035 | use U-2260 |
| 8680052 | March 2033 | use U-2979 |
| 9427448 | November 2030 | use U-1926 |
| 9925265 | May 2029 | use U-2260 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.